Neutrophils from CGD patients are defective in NETosis, and gene therapy results in restored NETosis in NADPH oxidase-competent neutrophils in vitro (Fuchs et al., 2007; Bianchi et al., 2009). Here, FMO5 is linked to chronic granulomatous disease.